Literature DB >> 28236063

Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.

Christian Baastrup Søndergaard1, David Scheie2, Astrid Marie Sehested3, Jane Skjøth-Rasmussen4.   

Abstract

INTRODUCTION: In 2016, the WHO classification of diffuse astrocytoma began to include isocitrate dehydrogenase (IDH) mutation in addition to histology.
RESULTS: We here demonstrate a case where a 14-year-old boy presented with a parietal tumor with no histological evidence of neoplasia but with an IDH1 mutation. Due to the IDH1 R132H mutation, the patient was diagnosed with diffuse astrocytoma WHO grade II and underwent successful gross total resection of this near-eloquently located tumor.
CONCLUSION: This case exemplifies how inclusion of immunohistochemistry in tumor classification alters surgical strategy and might improve accuracy and time to diagnosis.

Entities:  

Keywords:  Diffuse astrocytoma; IDH1 R132H mutation; Isocitrate dehydrogenase

Mesh:

Substances:

Year:  2017        PMID: 28236063     DOI: 10.1007/s00381-017-3348-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  10 in total

1.  Monoclonal antibody specific for IDH1 R132H mutation.

Authors:  David Capper; Hanswalter Zentgraf; Jörg Balss; Christian Hartmann; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-10-02       Impact factor: 17.088

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Surgical strategy in grade II astrocytoma: a population-based analysis of survival and morbidity with a strategy of early resection as compared to watchful waiting.

Authors:  Asgeir Store Jakola; Geirmund Unsgård; Kristin Smistad Myrmel; Roar Kloster; Sverre Helge Torp; Ole Kristian Losvik; Sigurd Lindal; Ole Solheim
Journal:  Acta Neurochir (Wien)       Date:  2013-09-17       Impact factor: 2.216

4.  Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.

Authors:  Sandra Camelo-Piragua; Michael Jansen; Aniruddha Ganguly; J Chulmin Kim; David N Louis; Catherine L Nutt
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

5.  Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up.

Authors:  Hugues Duffau
Journal:  Acta Neurochir (Wien)       Date:  2015-11-03       Impact factor: 2.216

6.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

7.  Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.

Authors:  Tareq A Juratli; Daniel P Cahill; Ian E McCutcheon
Journal:  Expert Rev Anticancer Ther       Date:  2015-05-17       Impact factor: 3.627

Review 8.  What do we know about IDH1/2 mutations so far, and how do we use it?

Authors:  Craig Horbinski
Journal:  Acta Neuropathol       Date:  2013-03-20       Impact factor: 15.887

Review 9.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

Review 10.  The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Manish K Aghi; Brian V Nahed; Andrew E Sloan; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.